Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields

Pancreatology

Volumn 14, Issue 1, 2014, Pages 54-63

  Giladi, Moshe ^a   Schneiderman, Rosa S ^a   Porat, Yaara ^a   Munster, Mijal ^a   Itzhaki, Aviran ^a   Mordechovich, Daniel ^a   Cahal, Shay ^a   Kirson, Eilon D ^a   Weinberg, Uri ^a   Palti, Yoram ^a  

^a Novocure GmbH   (Israel)

Author keywords

Anti mitotic; Cell volume; Clonogenic assay; TTFields

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SIZE; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DISRUPTION; CELL POPULATION; CELL VOLUME; CLONOGENESIS; CLONOGENIC ASSAY; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS; MONOTHERAPY; NON INVASIVE PROCEDURE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SYRIAN HAMSTER; TUMOR TREATING FIELDS;

ANTI-MITOTIC; CELL VOLUME; CLONOGENIC ASSAY; TTFIELDS;

ANIMALS; CELL LINE, TUMOR; CELL SIZE; COMBINED MODALITY THERAPY; CRICETINAE; DEOXYCYTIDINE; ELECTRICITY; HUMANS; MALE; MESOCRICETUS; MITOSIS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR STEM CELL ASSAY;

EID: 84900434404     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2013.11.009     Document Type: Article

References (29)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER cancer statistics review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013. Available at: http://seer.cancer.gov/csr/1975-2010/. Based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
2. Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004;64(9):3288-95.
3. Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007;104(24):10152-7.
4. Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis 2009;26(7):633-40.
5. Kirson ED, Schneiderman RS, Dbaly V, Tovarys F, Vymazal J, Itzhaki A, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 2009;9:1.
6. Salzberg M, Kirson E, Palti Y, Rochlitz C. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
7. Schneiderman RS, Shmueli E, Kirson ED, Palti Y. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer 2010;10:229.
8. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48(14):2192-202.
9. Pless M, Weinberg U. Tumor treating fields: concept, evidence and future. Expert Opin Investig Drugs 2011;20(8):1099-106.
10. Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I/II trial of TTFields therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer in press.
11. Egami H, Takiyama Y, Pour PM. Induction of multifocal pancreatic cancer after inoculation of hamster pancreatic cancer cell line (PC-1) into a defined area of homologous pancreatic tissue. Cancer Lett 1990;50(1):53-6.
12. Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A 2000;97(16):9180-5.
13. Scaiewicz V, Sorin V, Fellig Y, Birman T, Mizrahi A, Galula J, et al. Use of H19 gene regulatory Sequences in DNA-based therapy for pancreatic cancer. J Oncol 2010;2010:178174.
14. Hayflick L. The limited in vitro Lifetime of human Diploid cell Strains. Exp Cell Res 1965;37:614-36.
15. Weerasinghe P, Buja LM. Oncosis: an important non-apoptotic mode of cell death. Exp Mol Pathol 2012;93(3):302-8.
16. Steen HB, Lindmo T. Cellular and nuclear volume during the cell cycle of NHIK 3025 cells. Cell Tissue Kinet 1978;11(1):69-81.
17. Meistrich ML, Meyn RE, Barlogie B. Synchronization of mouse L-P59 cells by centrifugal elutriation separation. Exp Cell Res. 1977;105(1):169-77.
18. Fonkem E, Wong ET. NovoTTF-100A: a new treatment modality for recurrent glioblastoma. Expert Rev Neurother 2012;12(8):895-9.
19. Lee SX, Tunkyi A, Wong ET, Swanson KD. Lab-cell biology and signaling. Neuro Oncol 2012;14(Suppl. 6):vi7-20.
20. Lang F, Busch GL, Ritter M, Volkl H, Waldegger S, Gulbins E, et al. Functional significance of cell volume regulatory mechanisms. Physiol Rev 1998;78(1): 247-306.
21. Rave-Frank M, Virsik-Kopp P, Pradier O, Nitsche M, Grunefeld S, Schmidberger H. In vitro response of human dermal fibroblasts to X-irradiation: relationship between radiation-induced clonogenic cell death, chromosome aberrations and markers of proliferative senescence or differentiation. Int J Radiat Biol 2001;77(12):1163-74.
22. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4(8):592-603.
23. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9(5):353-63.
24. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 2005;65(18):8433-41.
25. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006;12(9):440-50.
26. Kajstura M, Halicka HD, Pryjma J, Darzynkiewicz Z. Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete "sub-G1" peaks on DNA content histograms. Cytometry A 2007;71(3):125-31.
27. Trump BF, Berezesky IK, Chang SH, Phelps PC. The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol Pathol 1997;25(1):82-8.
28. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutantenriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143(2):545-54.
29. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003;22(37):5866-75.